RSS-Feed abonnieren
DOI: 10.1055/s-2002-20564
Heparin Inhibition of Selectin-Mediated Interactions during the Hematogenous Phase of Carcinoma Metastasis: Rationale for Clinical Studies in Humans
Publikationsverlauf
Publikationsdatum:
05. März 2002 (online)
ABSTRACT
Classic studies indicate that the formation of tumor cell-platelet complexes in the blood stream is important in facilitating the metastatic process. Metastasis in animal models can be inhibited by heparin, and retrospective analyses of heparin use in human cancer have shown promise. However, most follow-up human studies using vitamin K antagonists have failed, and conclusive proof for other previously proposed mechanisms of heparin action is lacking. Carcinoma progression and metastasis are associated with overexpression of sialylated fucosylated mucins. Structurally similar molecules happen to be natural ligands for vascular adhesion molecules called the selectins. Heparin also happens to be a good inhibitor of P-selectin, which is expressed on activated platelets or endothelial cells. We have found that heparin blocks P-selectin-mediated interactions of endogenous platelets with sialylated fucosylated mucins on circulating carcinoma cells and that this reduces tumor cell survival. The use of more specific and selective P-selectin inhibitors will some day help to dissect the relative importance of this mechanism of heparin action in cancer. Meanwhile, we suggest that the failure of vitamin K antagonists to improve cancer prognosis should be ignored and that heparin therapy should be immediately revisited under this new paradigm. Unlike the suggestions in most previous studies, we propose that heparin use should be reexplored specifically during the interval from initial visualization of a primary tumor until just after its definitive surgical removal. A suggested clinical trial is outlined.
KEYWORD
Carcinomas - mucins - platelets - P-selectin - heparin
REFERENCES
- 1 Hart I R, Liotta L A. Developments in Oncology 7: Tumor Invasion and Metastasis. The Hague: Martinus Nijhoff 1982
- 2 Fidler I J. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award lecture. Cancer Res . 1990; 50 6130-6138
- 3 Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev . 1990; 9 171-174
- 4 Kerbel R S. Significance of tumor-host interactions in cancer growth and metastases. Cancer Metastasis Rev . 1995; 14 259-262
- 5 Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med . 1981; 95 636-641
- 6 Gasic G J. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev . 1984; 3 99-114
- 7 Honn K V, Tang D G, Crissman J D. Platelets and cancer metastasis: a causal relationship?. Cancer Metastasis Rev . 1992; 11 325-351
- 8 Honn K V, Tang D G, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost . 1992; 18 392-415
- 9 Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood . 1984; 63 55-63
- 10 Tanaka N G, Tohgo A, Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. V. In situ roles of platelets in hematogenous metastases. Invasion Metastasis . 1986; 6 209-224
- 11 Tohgo A, Tanaka N G, Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. IV. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent lung colonization. Invasion Metastasis . 1986; 6 58-68
- 12 Felding-Habermann B, Habermann R, Saldivar E, Ruggeri Z M. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem . 1996; 271 5892-5900
- 13 Kato Y, Fujita N, Yano H, Tsuruo T. Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule. Cancer Res . 1997; 57 3040-3045
- 14 Nieswandt B, Hafner M, Echtenacher B, Männel D N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res . 1999; 59 1295-1300
- 15 Karpatkin S, Pearlstein E, Ambrogio C, Coller B S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest . 1988; 81 1012-1019
- 16 Borsig L, Wong R, Feramisco J. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA . 2001; 98 3352-3357
- 17 Zacharski L R, Ornstein D L. Heparin and cancer. Thromb Haemost . 1998; 80 10-23
- 18 Engelberg H. Actions of heparin that may affect the malignant process. Cancer . 1999; 85 257-272
- 19 Hejna M, Raderer M, Zielinski C C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst . 1999; 91 22-36
- 20 Ornstein D L, Zacharski L R. The use of heparin for treating human malignancies. Haemostasis . 1999; 29(Suppl 1) 48-60
- 21 Smorenburg S M, Hettiarachchi R JK, Vink R, Büller H R. The effects of unfractionated heparin on survival in patients with malignancy-a systematic review. Thromb Haemost . 1999; 82 1600-1604
- 22 Smorenburg S M, Van Noorden J F C. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev . 2001; 53 93-105
- 23 Fielding L P, Hittinger R, Grace R H, Fry J S. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet . 1992; 340 502-506
- 24 Lebeau B, Chastang C, Brechot J M. Subcutaneous heparin treatment increases survival in small cell lung cancer. ``Petites Cellules'' Group. Cancer . 1994; 74 38-45
- 25 Kingston R D, Fielding J W, Palmer M K. Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer?. Int J Colorectal Dis . 1993; 8 111-115
- 26 Kakkar A K, Hedges R A, Williamson R CN, Kakkar V V. Perioperative heparin therapy inhibits late death from metastatic cancer. Int J Oncol . 1995; 6 885-888
- 27 Nitti D, Wils J, Sahmoud T. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). Eur J Cancer [A] . 1997; 33A 1209-1215
- 28 Hettiarachchi R JK, Smorenburg S M, Ginsberg J. Do heparins do more than just treat thrombosis?. <~>The influence of heparins on cancer spread. Thromb Haemost . 1999; 82 947-952
- 29 Kakkar A K, Williamson R CN. Antithrombotic therapy in cancer-low molecular weight heparins may have a direct effect on tumours. Br Med J . 1999; 318 1571-1572
- 30 Zacharski L R, Ornstein D L, Mamourian A C. Low-molecular-weight heparin and cancer. Semin Thromb Hemost . 2000; 26(Suppl 1) 69-77
- 31 Mueller B M, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest . 1998; 101 1372-1378
- 32 Palumbo J S, Kombrinck K W, Drew A F. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood . 2000; 96 3302-3309
- 33 Zacharski L R. Basis for selection of anticoagulant drugs for therapeutic trials in human malignancy. Haemostasis . 1986; 16 300-320
- 34 Zacharski L R, Henderson W G, Rickles F R. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer . 1984; 53 2046-2052
- 35 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med . 2000; 342 1953-1958
- 36 Taylor-Papadimitriou J, Burchell J, Miles D W, Dalziel M. MUC1 and cancer. Biochim Biophys Acta Mol Basis Dis . 1999; 1455 301-313
- 37 Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res . 1996; 56 2237-2244
- 38 Kim Y J, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J . 1997; 14 569-576
- 39 Hakomori S, Zhang Y. Glycosphingolipid antigens and cancer therapy. Chem Biol . 1997; 4 97-104
- 40 Dennis J W, Granovsky M, Warren C E. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta Gen Subj . 1999; 1473 21-34
- 41 Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J . 1997; 14 577-584
- 42 Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res . 1996; 56 5309-5318
- 43 Zhang K, Sikut R, Hansson G C. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol . 1997; 176 158-165
- 44 Kim Y S, Gum J, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J . 1996; 13 693-707
- 45 Matsushita Y, Yamamoto N, Shirahama H. Expression of sulfomucins in normal mucosae, colorectal adenocarcinomas, and metastases. Jpn J Cancer Res . 1995; 86 1060-1067
- 46 Bresalier R S, Niv Y, Byrd J C. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest . 1991; 87 1037-1045
- 47 Spicer A P, Rowse G J, Lidner T K, Gendler S J. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem . 1995; 270 30093-30101
- 48 Sack G HJ, Levin J, Bell W R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore ) . 1977; 56 1-37
- 49 Callander N, Rapaport S I. Trousseau's syndrome. West J Med . 1993; 158 364-371
- 50 Rickles F R, Levine M N. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis . 1998; 28(Suppl 3) 43-49
- 51 Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost . 1997; 78 141-144
- 52 Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer . 1997; 80 649-655
- 53 Levine M, Hirsh J, Gent M. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet . 1994; 343 886-889
- 54 Magnani J L, Brockhaus M, Smith D F, Ginsburg V. Detection of glycolipid ligands by direct binding of carbohydrate-binding proteins to thin-layer chromatograms. Methods Enzymol . 1982; 83 235-241
- 55 Fukushima K, Hirota M, Terasaki P I. Characterization of sialosylated Lewis X as a new tumor-associated antigen. Cancer Res . 1984; 44 5279-5285
- 56 Hoff S D, Matsushita Y, Ota D M. Increased expression of sialyl-dimeric Le antigen in liver metastases of human colorectal carcinoma. Cancer Res . 1989; 49 6883-6888
- 57 Iwanari O, Miyako J, Date Y. Clinical evaluations of the tumor marker sialyl SSEA-antigen for clinical gynecological disease. Gynecol Obstet Invest . 1990; 29 214-218
- 58 Matsushita Y, Cleary K R, Ota D M, Hoff S D, Irimura T. Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. Lab Invest . 1990; 63 780-791
- 59 Matsusako T, Muramatsu H, Shirahama T, Muramatsu T, Ohi Y. Expression of a carbohydrate signal, sialyl dimeric LeX antigen, is associated with metastatic potential of transitional cell carcinoma of the human urinary bladder. Biochem Biophys Res Commun . 1991; 181 1218-1222
- 60 Shirahama T, Ikoma M, Muramatsu H, Muramatsu T, Ohi Y. Reactivity to fucose-binding proteins of lotus tetragonolobus correlates with metastatic phenotype of transitional cell carcinoma of the bladder. J Urol . 1992; 147 1659-1664
- 61 Sinn H-P, Brown S A, Oberle E, Thompson J S. Analysis of the Lewisx epitope in human pancreas and pancreatic adenocarcinomas. Int J Pancreatol . 1992; 11 125-135
- 62 Nakamori S, Kameyama M, Imaoka S. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res . 1993; 53 3632-3637
- 63 Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. Expression of sialyl Lewisa as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer . 1995; 75 2051-2056
- 64 Ogawa J, Inoue H, Koide S. Expression of α-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer. Cancer Res . 1996; 56 325-329
- 65 Idikio H A. Sialyl-Lewis-X. Gleason grade and stage in non-metastatic human prostate cancer. Glycoconj J . 1997; 14 875-877
- 66 Nakamori S, Kameyama M, Imaoka S. Involvement of carbohydrate antigen sialyl Lewisx in colorectal cancer metastasis. Dis Colon Rectum . 1997; 40 420-431
- 67 Weimbs T, Mostov K, Low S H, Hofmann R. A model for structural similarity between different SNARE complexes based on sequence relationships. Trends Cell Biol . 1998; 8 260-262
- 68 Nakagoe T, Fukushima K, Nanashima A. Increased expression of sialyl Lex antigen in non-polypoid growth type of colorectal carcinoma. Cancer Lett . 2000; 151 209-216
- 69 Benharroch D, Dima E, Levy A. Differential expression of sialyl and non-sialyl-CD15 antigens on Hodgkin-Reed-Sternberg cells: significance in Hodgkin's disease. Leuk Lymphoma . 2000; 39 185-194
- 70 Springer T A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell . 1994; 76 301-314
- 71 Kansas G S. Selectins and their ligands: current concepts and controversies. Blood . 1996; 88 3259-3287
- 72 McEver R P. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J . 1997; 14 585-591
- 73 Varki A. Selectin ligands: will the real ones please stand up?. J Clin Invest . 1997; 99 158-162
- 74 McEver R P, Cummings R D. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest . 1997; 100 485-492
- 75 Hemmerich S, Rosen S D. Carbohydrate sulfotransferases in lymphocyte homing. Glycobiology . 2000; 10 849-856
- 76 Somers W S, Tang J, Shaw G D, Camphausen R T. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell . 2000; 103 467-479
- 77 Stone J P, Wagner D D. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest . 1993; 92 804-813
- 78 Mannori G, Crottet P, Cecconi O. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin type glycoproteins. Cancer Res . 1995; 55 4425-4431
- 79 Aigner S, Sthoeger Z M, Fogel M. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood . 1997; 89 3385-3395
- 80 Crottet P, Kim Y J, Varki A. Subsets of sialylated, sulfated mucins of diverse origins are recognized by L-selectin. Lack of evidence for unique oligosaccharide sequences mediating binding. Glycobiology . 1996; 6 191-208
- 81 Kim Y J, Borsig L, Han H L, Varki N M, Varki A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol . 1999; 155 461-472
- 82 Kim Y J, Borsig L, Varki N M, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA . 1998; 95 9325-9330
- 83 Takada A, Ohmori K, Yoneda T. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res . 1993; 53 354-361
- 84 Lorant D E, Topham M K, Whatley R E. Inflammatory roles of P-selectin. J Clin Invest . 1993; 92 559-570
- 85 Diacovo T G, Puri K D, Warnock R A, Springer T A, von Andrian H U. Platelet-mediated lymphocyte delivery to high endothelial venules. Science . 1996; 273 252-255
- 86 McCarty O J, Mousa S A, Bray P F, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood . 2000; 96 1789-1797
- 87 Mellors A, Lo R YC. O-Sialoglycoprotease from Pasteurella haemolytica Methods Enzymol . 1995; 248 728-740
- 88 Nelson R M, Cecconi O, Roberts W G. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood . 1993; 82 3253-3258
- 89 Norgard-Sumnicht K E, Varki N M, Varki A. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science . 1993; 261 480-483
- 90 Koenig A, Norgard-Sumnicht K E, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins-implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest . 1998; 101 877-889
- 91 Ma Y Q, Geng J G. Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol . 2000; 165 558-565
- 92 Xie X, Rivier A S, Zakrzewicz A. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides-studies with carboxyl-reduced and sulfated heparin and with trestatin A sulfate. J Biol Chem . 2000; 275 30718-30711
- 93 Varki A, Varki N M. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic potential. Braz J Med Biol Res . 2001; 34 711-717
- 94 Fidler I J, Schroit A J. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta . 1988; 948 151-173
- 95 Sawada R, Tsuboi S, Fukuda M. Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem . 1994; 269 1425-1431
- 96 Izumi Y, Taniuchi Y, Tsuji T. Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: liver colonization and adhesion to vascular endothelial cells. Exp Cell Res . 1995; 216 215-221
- 97 Mannori G, Santoro D, Carter L. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol . 1997; 151 233-243
- 98 Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J . 1999; 18 1516-1525
- 99 Leppänen A, Mehta P, Ouyang Y B. A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin. J Biol Chem . 1999; 274 24838-24848
- 100 Yang J, Hirata T, Croce K. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med . 1999; 190 1769-1782
- 101 Handa K, White T, Ito K. P-Selectin-dependent adhesion of human cancer cells: requirement for co-expression of a `PSGL-1-like' core protein and the glycosylation process for sialosyl-Lex or sialosyl-Lea . Int J Oncol . 1995; 6 773-781
- 102 Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol . 2001; 11 75-82
- 103 Hirsh J, Warkentin T E, Shaughnessy S G. Heparin and low-molecular-weight heparin-mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest . 2001; 119(Suppl) 64S-94S
- 104 Agnelli G. Pharmacological activities of heparin chains: should our past knowledge be revised?. Haemostasis . 1996; 26(Suppl 2) 2-9
- 105 Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate: a piece of information. FASEB J . 1996; 10 1270-1279
- 106 Miao H Q, Elkin M, Aingorn E. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer . 1999; 83 424-431
- 107 Parish C R, Freeman C, Brown K J, Francis D J, Cowden W B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res . 1999; 59 3433-3441
- 108 Folkman J, Weisz P B, Joullié M M, Li W W, Ewing W R. Control of angiogenesis with synthetic heparin substitutes. Science . 1989; 243 1490-1493
- 109 Fareed J, Hoppensteadt D A, Bick R L. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost . 2000; 26(Suppl 1) 5-21
- 110 Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?. Thromb Res . 2000; 100 V113-V120
- 111 Van der Heijden F J, Prins M H, Büller H R. Low-molecular-weight heparins: are they interchangeable?. Haemostasis . 2000; 30(Suppl 2) 148-157
- 112 Huang J N, Shimamura A. Low-molecular-weight heparins. Hematol Oncol Clin North Am . 1998; 12 1251-1281
- 113 Valentine K A, Hull R D, Pineo G F. Low-molecular-weight heparin therapy and mortality. Semin Thromb Hemost . 1997; 23 173-178
- 114 Kakkar A K, Williamson R CN. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost . 1999; 25 239-243
- 115 Brown D C, Purushotham A D, Birnie G D, George W D. Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery . 1995; 117 95-101
- 116 Al-Mehdi A B, Tozawa K, Fisher A B. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med . 2000; 6 100-102